Table 1. Reasonable Doses and Schedules by Recommendation
Note: only recommendations with recommended therapy are listed
(cont'd)
IDH-mutant Astrocytic and Oligodendroglial Tumors (cont'd)
Recommendation Therapy Dose and Schedule Source
Recommendation 2.4
(newly diagnosed
supratentorial
glioblastoma
multiforme (GBM)
who have completed
chemoradiation
therapy)
Alternating
electric field
therapy
Daily use, >18 hours
per day, until 2nd
progression
See EF-14
trial protocol
for details on
therapy
Recommendation 2.6
(patients where the
expected survival
benefits of a six-week
radiation course
combined with
temozolomide may not
outweigh the harms)
Hypofractionated
radiation
40.05 Gy in 15
fractions over 3 weeks
As used in Perry,
et al 2017
Concurrent
temozolomide
75 mg/m
2
daily for
21 days
As used in
Perry, et al 2017
Adjuvant
temozolomide
150–200 mg/m
2
for 5
out of 28 consecutive
days for a maximum of
12 months
As used in
Perry, et al 2017
Recommendation 2.7
(patients with older
age, poor performance
status, or with concerns
about toxicity or
prognosis)
Hypofractionated
radiation alone
40 Gy in 15 fractions
over 3 weeks
As used in Roa,
et al 2004
Temozolomide
alone
100 mg/m
2
on days
1–7 of every 2 weeks
until progression
OR
200 mg/m
2
on days
1–5 of every 28 days
for up to six cycles)
As used in
NOA-08 trial
As used in
Nordic Trial
